MX2010004554A - Composiciones y métodos para el tratamiento de inflamación. - Google Patents
Composiciones y métodos para el tratamiento de inflamación.Info
- Publication number
- MX2010004554A MX2010004554A MX2010004554A MX2010004554A MX2010004554A MX 2010004554 A MX2010004554 A MX 2010004554A MX 2010004554 A MX2010004554 A MX 2010004554A MX 2010004554 A MX2010004554 A MX 2010004554A MX 2010004554 A MX2010004554 A MX 2010004554A
- Authority
- MX
- Mexico
- Prior art keywords
- electrokinetically
- fluids
- generated
- therapeutic compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
Abstract
Se proveen fluidos generados electrocinéticamente (por ejemplo, fluidos o soluciones electrocinéticas enriquecidas con gas), y composiciones terapéuticas y métodos para usarse en el tratamiento de inflamación o al menos un síntoma de inflamación. Los fluidos generados electrocinéticamente o composiciones terapéuticas y métodos incluyen fluidos acuosos generados electrocinéticamente opcionalmente en combinación con otros agentes terapéuticos. Aspectos particulares proveen la regulación o modulación de transducción de señal intracelular asociada con respuestas inflamatorias mediante modulación de al menos una membrana celular, potencial de membrana, proteínas de membrana tales como receptores de membrana, incluyendo pero sin limitación, receptores acoplados a proteína G (GPCR), y uniones intercelulares (por ejemplo, uniones estrechas, uniones con espacio, adherinas zona y desmasomas). Otras modalidades incluyen rutas particulares de administración o formulaciones para los fluidos generados electrocinéticamente (por ejemplo, fluidos y soluciones enriquecidos con gas generadas electrocinéticamente) y composiciones terapéuticas.
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98271907P | 2007-10-25 | 2007-10-25 | |
US98272007P | 2007-10-25 | 2007-10-25 | |
PCT/US2007/082581 WO2008115290A2 (en) | 2006-10-25 | 2007-10-25 | Methods of wound care and treatment |
PCT/US2007/082578 WO2008052143A2 (en) | 2006-10-25 | 2007-10-25 | Mixing device and output fluids of same |
PCT/US2007/082580 WO2008052145A2 (en) | 2006-10-25 | 2007-10-25 | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
US4833208P | 2008-04-28 | 2008-04-28 | |
US4834008P | 2008-04-28 | 2008-04-28 | |
US4840408P | 2008-04-28 | 2008-04-28 | |
US4834708P | 2008-04-28 | 2008-04-28 | |
PCT/US2008/081202 WO2009055729A1 (en) | 2007-10-25 | 2008-10-24 | Compositions and methods for treating inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010004554A true MX2010004554A (es) | 2010-07-28 |
Family
ID=42261767
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010004563A MX2010004563A (es) | 2007-10-25 | 2008-10-23 | Composiciones y métodos para modular la transducción de la señal intracelular mediada por la membrana celular. |
MX2010004564A MX2010004564A (es) | 2007-10-25 | 2008-10-24 | Composiciones y métodos para tratamiento de fibrosis quística. |
MX2010004554A MX2010004554A (es) | 2007-10-25 | 2008-10-24 | Composiciones y métodos para el tratamiento de inflamación. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010004563A MX2010004563A (es) | 2007-10-25 | 2008-10-23 | Composiciones y métodos para modular la transducción de la señal intracelular mediada por la membrana celular. |
MX2010004564A MX2010004564A (es) | 2007-10-25 | 2008-10-24 | Composiciones y métodos para tratamiento de fibrosis quística. |
Country Status (8)
Country | Link |
---|---|
EP (3) | EP2215260A4 (es) |
JP (6) | JP5613565B2 (es) |
CN (5) | CN101910412B (es) |
AU (3) | AU2008316794B2 (es) |
CA (3) | CA2703672A1 (es) |
IL (3) | IL205317A (es) |
MX (3) | MX2010004563A (es) |
WO (1) | WO2009055614A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
AU2007308838B2 (en) | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
AU2007308840C1 (en) | 2006-10-25 | 2014-09-25 | Revalesio Corporation | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
CA2703648A1 (en) * | 2007-10-25 | 2009-04-30 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
JP5539965B2 (ja) * | 2008-04-28 | 2014-07-02 | レバレジオ コーポレイション | 多発性硬化症を治療するための組成物および方法 |
EP2285347A4 (en) | 2008-05-01 | 2011-09-21 | Revalesio Corp | COMPOSITIONS AND METHODS OF TREATING DISORDERS OF THE DIGESTION SYSTEM |
AU2009308362B2 (en) * | 2008-10-22 | 2016-02-04 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (TSLP)-mediated conditions |
CA2758738A1 (en) * | 2009-04-27 | 2010-11-04 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
BR112012028540A2 (pt) * | 2010-05-07 | 2016-07-26 | Revalesio Corp | composições e métodos para melhorar desempenho fisiológico e tempo de recuperação |
EP2582373A4 (en) | 2010-06-16 | 2013-10-30 | Bruce Chandler May | USE OF LEVOCETIRIZIN AND MONTELUKAST IN THE TREATMENT OF INFLUENZA, COLLECTIONS AND INFLAMMATION |
AU2011289172B2 (en) | 2010-08-12 | 2015-09-24 | Revalesio Corporation | Compositions and methods for treatment of taupathy |
JP2013538803A (ja) * | 2010-08-13 | 2013-10-17 | レバレジオ コーポレイション | 心血管疾患を治療するための組成物および方法 |
US20120263764A1 (en) * | 2011-04-13 | 2012-10-18 | Revalesio Corporation | Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease |
JP6368459B2 (ja) * | 2012-06-14 | 2018-08-01 | 松本 高明 | 点眼液の製造方法 |
RU2672871C2 (ru) | 2013-03-13 | 2018-11-20 | Инфламматори Респонс Ресёрч, Инк. | Применение левоцетиризина и монтелукаста при лечении травматических повреждений |
RU2015134423A (ru) | 2013-03-13 | 2017-04-26 | Инфламматори Респонс Ресёрч, Инк. | Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств |
CA2901413A1 (en) | 2013-03-13 | 2014-10-09 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of vasculitis |
EP3193875B1 (en) | 2014-09-15 | 2022-02-16 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
CN106943593A (zh) * | 2017-03-24 | 2017-07-14 | 浙江中医药大学 | 抗tslp抗体在制备防治慢性瘙痒药物中的应用 |
US20200069750A1 (en) * | 2017-05-23 | 2020-03-05 | Biovite Australia Pty Ltd | Extracts from arthrospira and uses thereof |
CN112305153B (zh) * | 2020-10-16 | 2022-09-23 | 中石化石油工程技术服务有限公司 | 一种膨润土含量的自动分析检测仪及其检测方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9518483D0 (en) * | 1995-09-09 | 1995-11-08 | Thompson Royce Ltd | Lighting control systems |
US6386751B1 (en) * | 1997-10-24 | 2002-05-14 | Diffusion Dynamics, Inc. | Diffuser/emulsifier |
US7654728B2 (en) * | 1997-10-24 | 2010-02-02 | Revalesio Corporation | System and method for therapeutic application of dissolved oxygen |
AU764180B2 (en) * | 1998-07-28 | 2003-08-14 | Regents Of The University Of California, The | Nucleic acids encoding a G-protein coupled receptor involved in sensory transduction |
KR100581441B1 (ko) * | 1999-10-26 | 2006-05-23 | 바이오-하이드레이션 리서치 랩 인코포레이티드 | 마이크로-클러스터 액체 및 이의 제조방법과 사용방법 |
US20060198901A9 (en) * | 1999-10-26 | 2006-09-07 | Holloway William D Jr | Drugs, bio-affecting and body treating compositions |
JP2003516150A (ja) * | 1999-12-08 | 2003-05-13 | ジェンセット | 潜在性分泌タンパク質をコードする全長ヒトcDNA |
US7255881B2 (en) * | 2000-07-27 | 2007-08-14 | Nucryst Pharmaceuticals Corp. | Metal-containing materials |
US20020107197A1 (en) * | 2000-09-20 | 2002-08-08 | Yan Xu | Ligands for G protein coupled receptors and methods of using them |
US20040235732A1 (en) * | 2000-11-03 | 2004-11-25 | Qun-Yong Zhou | Method for modulating angiogenesis using prokineticin receptor antagonists |
US6649145B2 (en) * | 2001-02-01 | 2003-11-18 | Hydron Technologies, Inc. | Compositions and method of tissue superoxygenation |
GB0118383D0 (en) * | 2001-07-27 | 2001-09-19 | Pharmagene Lab Ltd | Therapeutic methods |
DE10227818A1 (de) * | 2002-06-21 | 2004-01-08 | Pakdaman, Abolghassem, Prof. Dr.med. | Gasanreicherungsmodule |
AU2002321678A1 (en) * | 2002-09-09 | 2004-03-29 | Boros Béla | Oxygen-enriched water, treated within a magnetic field and heavy water |
US7790762B2 (en) * | 2002-10-31 | 2010-09-07 | National Jewish Health | Compounds and methods for thiol-containing compound efflux and cancer treatment |
US7491695B2 (en) * | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
US20090074890A1 (en) * | 2003-11-10 | 2009-03-19 | Park Min K | Substituted Triazoles as Sodium Channel Blockers |
US20050139808A1 (en) * | 2003-12-30 | 2005-06-30 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and process for producing same |
WO2005113026A2 (en) * | 2004-04-22 | 2005-12-01 | Medical Discoveries, Inc. | Method of treating respiratory disorders and airway inflammation |
DE602005014393D1 (de) * | 2005-03-28 | 2009-06-18 | Dabur Pharma Ltd | Stabile pharmazeutische zusammensetzungen aus antitumoralen platin-(ii)-mitteln |
DK1901749T3 (en) * | 2005-05-18 | 2016-10-24 | Raptor Pharmaceuticals Inc | Aerosolized fluoroquinolones AND USES THEREOF |
GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
AU2007308840C1 (en) * | 2006-10-25 | 2014-09-25 | Revalesio Corporation | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
AU2007308838B2 (en) * | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
CA2667614A1 (en) * | 2006-10-25 | 2008-09-25 | Revalesio Corporation | Method of wound care and treatment |
CA2703648A1 (en) * | 2007-10-25 | 2009-04-30 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
-
2008
- 2008-10-23 EP EP08842968A patent/EP2215260A4/en not_active Withdrawn
- 2008-10-23 JP JP2010531255A patent/JP5613565B2/ja not_active Expired - Fee Related
- 2008-10-23 WO PCT/US2008/081021 patent/WO2009055614A1/en active Application Filing
- 2008-10-23 MX MX2010004563A patent/MX2010004563A/es active IP Right Grant
- 2008-10-23 CA CA2703672A patent/CA2703672A1/en not_active Abandoned
- 2008-10-23 AU AU2008316794A patent/AU2008316794B2/en not_active Ceased
- 2008-10-23 CN CN200880122893XA patent/CN101910412B/zh not_active Expired - Fee Related
- 2008-10-24 CN CN201410108422.0A patent/CN103933567A/zh active Pending
- 2008-10-24 AU AU2008316663A patent/AU2008316663B2/en not_active Ceased
- 2008-10-24 CN CN201510111837.8A patent/CN104771758A/zh active Pending
- 2008-10-24 CN CN200880122816.4A patent/CN101909623B/zh not_active Expired - Fee Related
- 2008-10-24 JP JP2010531276A patent/JP5911197B2/ja not_active Expired - Fee Related
- 2008-10-24 CA CA2703739A patent/CA2703739A1/en not_active Abandoned
- 2008-10-24 MX MX2010004564A patent/MX2010004564A/es active IP Right Grant
- 2008-10-24 EP EP08841701.9A patent/EP2214707B1/en active Active
- 2008-10-24 JP JP2010531290A patent/JP5869763B2/ja active Active
- 2008-10-24 AU AU2008316623A patent/AU2008316623B2/en active Active
- 2008-10-24 CN CN200880122817.9A patent/CN101909648B/zh active Active
- 2008-10-24 CA CA2703754A patent/CA2703754C/en active Active
- 2008-10-24 MX MX2010004554A patent/MX2010004554A/es active IP Right Grant
- 2008-10-24 EP EP08841991A patent/EP2224924A4/en not_active Withdrawn
-
2010
- 2010-04-25 IL IL205317A patent/IL205317A/en not_active IP Right Cessation
- 2010-04-25 IL IL205319A patent/IL205319A/en not_active IP Right Cessation
- 2010-04-25 IL IL205318A patent/IL205318A/en active IP Right Grant
-
2014
- 2014-06-06 JP JP2014117564A patent/JP2014193915A/ja active Pending
- 2014-06-12 JP JP2014121350A patent/JP2014169328A/ja not_active Withdrawn
- 2014-06-12 JP JP2014121357A patent/JP2014205693A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010004554A (es) | Composiciones y métodos para el tratamiento de inflamación. | |
MX337862B (es) | Composiciones y métodos para el tratamiento de la esclerosis multiple. | |
MX2011011333A (es) | Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion. | |
WO2009134929A3 (en) | Compositions and methods for treating digestive disorders | |
MX2013001636A (es) | Composiciones y metodos para el tratamiento de taupatias | |
EA201170601A1 (ru) | Модуляторы регулятора трансмембранной проводимости при муковисцидозе | |
AR114196A2 (es) | Anticuerpo anti-receptor de il-6 | |
PA8638701A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
PA8638801A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
AR066042A1 (es) | Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9) | |
EA201001223A1 (ru) | Стабилизированные белковые композиции | |
CR8789A (es) | Anticuerpos que se unen a il-13 | |
UY30573A1 (es) | N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2 | |
CO6180433A2 (es) | Moleculas de enlace de lingo y uso farmaceutico de las mismas | |
MX2012000396A (es) | Metodos y composiciones para uso en tartamientos celulares. | |
UY29735A1 (es) | Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos | |
GT200800065A (es) | Métodos y composiciones para modular la hemostasia | |
TW200712059A (en) | Ionic liquids of low viscosity | |
AR074283A1 (es) | Composicion de champu concentrada. | |
WO2018115017A3 (en) | CRYSTALLINE STRUCTURE OF GREMLIN-1 AND ANTIBODY INHIBITOR | |
CO6180423A2 (es) | Forma farmaceutica que contiene metocarbamol, meloxicam y betametasona | |
ATE531703T1 (de) | Benzochromenderivate | |
GT201000119A (es) | "procedimiento para la preparacion de una bebida fermentada" | |
DE602007004081D1 (de) | 17-phosphor-steroid-derivate als progesteron-rezeptormodulatoren | |
ECSP066777A (es) | Derivados de furosemida como moduladores de hm74 y su uso para el tratamiento de inflamacion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |